Ongoing Clinical Trials for Rhegmatogenous Retinal Detachment
Currently, there is 1 ongoing clinical trial investigating new treatment approaches for rhegmatogenous retinal detachment, a serious eye condition where the retina separates from its underlying tissue. This trial is exploring whether a medication called ursodeoxycholic acid can help improve vision recovery after surgery for this condition.
Clinical trial locations
- France
Study on the Use of Ursodeoxycholic Acid for Patients Undergoing Surgery for Retinal Detachment
This clinical trial is investigating whether ursodeoxycholic acid (UDCA) can help patients recover better vision after undergoing surgery for rhegmatogenous retinal detachment. This condition occurs when the retina, the light-sensitive layer at the back of the eye, pulls away from its normal position due to a tear or break, which can lead to vision loss if not treated promptly.
Who can participate:
- Adults aged 18 years or older
- Patients scheduled for vitrectomy surgery, a procedure to remove the gel-like substance inside the eye
- Patients who either do not have a natural lens in their eye or have an artificial lens following cataract surgery
- Individuals whose retinal detachment affects at least half of the retina (2 or more quadrants)
- Participants must be affiliated with health insurance and sign a consent form
Who cannot participate:
- Patients whose retinal detachment surgery was not successful
- Those who have not had vitrectomy with gas tamponade, a specific surgical technique that uses gas to help the retina heal
- Patients who still have their natural lens in the affected eye
- Individuals who fall into vulnerable populations requiring special protection
What the trial involves:
The study aims to determine if UDCA, administered as a hard capsule called URSOLVAN 200 mg, can improve visual recovery following surgery. Participants will receive either UDCA or a placebo (an inactive substance). The medication is taken orally, with two capsules daily for four weeks after surgery.
Throughout the trial, researchers will measure visual acuity (the sharpness of vision) at multiple time points: immediately after surgery, and at 7, 30, 60, 90, and 180 days following the procedure. Additional assessments include measuring the thickness of the retina, evaluating the sensitivity of the macula (the central part of the retina responsible for detailed vision), and monitoring for any complications or side effects.
The investigational drug:
Ursodeoxycholic acid is traditionally used to treat liver conditions but is now being explored for its potential neuroprotective properties in eye health. In this context, it may help protect nerve cells in the retina by reducing oxidative stress and inflammation, potentially supporting better vision recovery after surgery. The study seeks to establish whether this medication provides meaningful benefits compared to placebo treatment.
The trial is expected to continue until July 2027, collecting comprehensive data on visual outcomes and eye health indicators to determine the effectiveness of UDCA in this patient population.
Summary
Currently, only one clinical trial is actively recruiting patients with rhegmatogenous retinal detachment. This study, conducted in France, focuses on evaluating ursodeoxycholic acid as a supportive treatment following surgical repair of retinal detachment. The trial represents an innovative approach to improving visual outcomes after surgery by investigating a medication traditionally used for other medical conditions. While the number of available trials is limited, this research offers patients who have undergone or are scheduled for retinal detachment surgery an opportunity to participate in advancing treatment options for this sight-threatening condition.
